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Abstract
Background: As middle-income countries become more affluent, economically sophisticated and productive, health 
expenditure patterns are likely to change. Other socio-demographic and political changes that accompany rapid 
economic growth are also likely to influence health spending and financial protection.
Methods: This study investigates the relationship between growth on per-capita healthcare expenditure and gross 
domestic product (GDP) in a group of 27 large middle-income economies and compares findings with those of 24 
high-income economies from the Organization for Economic Cooperation and Development (OECD) group. This 
comparison uses national accounts data from 1995-2014. We hypothesize that the aggregated income elasticity of health 
expenditure in middle-income countries would be less than one (meaning healthcare is a normal good). An initial 
exploratory analysis tests between fixed-effects and random-effects model specifications. A fixed-effects model with 
time-fixed effects is implemented to assess the relationship between the two measures. Unit root, Hausman and serial 
correlation tests are conducted to determine model fit. Additional explanatory variables are introduced in different 
model specifications to test the robustness of our regression results. We include the out-of-pocket (OOP) share of health 
spending in each model to study the potential role of financial protection in our sample of high- and middle-income 
countries. The first-difference of study variables is implemented to address non-stationarity and cointegration properties. 
Results: The elasticity of per-capita health expenditure and GDP growth is positive and statistically significant among 
sampled middle-income countries (51 per unit-growth in GDP) and high-income countries (50 per unit-growth in 
GDP). In contrast with previous research that has found that income elasticity of health spending in middle-income 
countries is larger than in high-income countries, our findings show that elasticity estimates can change if different 
criteria are used to assemble a more homogenous group of middle-income countries. Financial protection differences 
between middle- and high-income countries, however, are not associated with their respective income elasticity of health 
spending. `
Conclusion: The study findings show that in spite of the rapid economic growth experienced by the sampled middle-
income countries, the aggregated income elasticity of health expenditure in them is less than one, and equals that of 
high-income countries. 
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Background
As individuals become more affluent, they spend more on 
healthcare.1 A similar relationship exists across countries. 
High-income countries spend a higher share of their 
aggregate and per-capita incomes on healthcare compared to 
middle-income countries.2 A clear distinction between high- 
and middle-income countries, however, has become more 
ambiguous in recent years.3,4 In the last two decades many 
middle-income countries have been experiencing accelerated 
economic growth, rapid urbanization, social modernization, 
poverty reduction and changes in the composition of their 
national economies. In 1980, low- and middle-income 
countries accounted for 33.7% of global income whereas in 
2010, they accounted for 43.4% of global income and for most 
of the world’s economic growth.5
As middle-income countries become more affluent, 
economically sophisticated and productive, health 
expenditure patterns are likely to change. Other socio-
demographic and political changes that accompany rapid 
economic growth are also likely to influence health spending, 
such as government effectiveness, regulatory quality, voice and 
accountability.6,7 Population ageing is a global phenomenon 
that is expected to occur particularly rapidly in some middle-
income countries, predominantly in China and many Eastern 
European and Latin American countries8 while other middle-
income countries such as India and Nigeria would continue 
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Implications for policy makers
• Middle-income countries can benefit from shared knowledge on how to pair economic growth with more effective, efficient and fair healthcare 
systems. 
• Government planners in middle-income countries would benefit from a better understanding of how their economic and health system 
development compares with  those of high-income nations. 
Implications for the public
If present accelerated growth rates in middle-income countries continue, they are likely to have an increasing role in the world’s healthcare financing. 
This study shows middle-income countries allocate less money to healthcare, but as their economies grow, their health spending follows a trajectory 
similar to that in high-income countries. This study looks at the tradeoff between economic growth and health spending growth and finds that 
economic growth still increases faster than health spending. The rate of growth of health spending is also similar among sampled middle-income 
countries. Government planners should observe these trends carefully to identify whether health spending growth rates will follow a similar trajectory 
to those of high-income nations or if health spending in middle-income countries would evolve differently.
Key Messages 
to have higher share of young productive populations. 
In addition, economic reforms in many middle-income 
countries have been paired with social policies that procure 
better investments in human capita, such as conditional cash 
transfers programs, micro-credits and social health insurance 
programs.9,10 Economic prosperity is often times associated 
with increased governmental spending on healthcare and 
development of private health insurance markets to cater to 
emerging middle classes.11 
An extensive literature has investigated the link between 
economic growth and health spending to explain cross-
country variation across high-income countries in the 
Organization for Economic Cooperation and Development 
(OECD) economies.12 This literature concludes that aggregate 
national income is the most important factor explaining 
cross-country variation in per-capita healthcare expenditure 
among the high-income countries of the OECD.13,14 A 
substantial share of health expenditure heterogeneity across 
these countries, however, remains unexplained due to data 
challenges.15,16
During the 1980s and 1990s many studies found the income 
elasticity of healthcare expenditures[1] in high-income 
countries to be more than one, which implies that healthcare 
expenditures rise faster than incomes. These studies 
supported the argument that as economies grow, healthcare 
becomes a superior good rather than a normal good (which 
would have an elasticity less than one). However, this debate 
is far from settled due to data and methodological concerns. 
Many of these studies ignored the non-stationarity among 
variables leading to potentially spurious results from OLS 
regressions.14 Subsequent studies which utilized advances 
in statistical methods have accounted for non-stationarity 
and autocorrelation of panel data and have found elasticities 
lower than one among high-income countries of the OECD 
indicating that healthcare remains a normal good.15 
These analyses have recently been applied to the changing 
healthcare expenditure patterns of countries in different stages 
of economic development. Recent studies have implemented 
an income elasticity of health spending comparison between 
high-, middle- and low-income countries.6,7 They have 
investigated the role of institutional factors such as government 
effectiveness and accountability to explain differences across 
countries.6 These studies have found that the income elasticity 
of health spending is still less than one, although it is higher 
among middle-income countries compared to that in high-
income countries.6
As countries develop, they are more likely to provide better 
financial protection from the consequences of health events 
through better health insurance mechanisms.17 High-income 
countries have more resources to provide better financial 
protection through more comprehensive public health 
insurance plans and a multiplicity of supplemental private 
health insurance plans. In contrast, public health insurance 
coverage in middle-income countries could be less generous, 
and supplemental private health insurance unavailable or 
inadequate. Thus, individuals in these countries may be 
more likely to pay for healthcare expenditures out-of-pocket 
(OOP) in the private sector. No study to our knowledge has 
investigated the role of financial protection in explaining 
differences in the income elasticity of health spending in 
middle- and high-income countries.
Implementing such a comparison is challenging, as country 
heterogeneity among middle-income countries is even 
more pronounced than heterogeneity across high-income 
countries. Studies advocate for alternative approaches to 
classifying countries based on cluster analysis.3,4 This study 
follows these recommendations, conducting a comparison in 
a subset of middle-income countries with large economies, 
populations and global influence. 
Differences Between Middle-Income and High-Income 
Countries
Middle-income countries are expected to experience 
increases in healthcare expenditures with growth in their 
gross domestic products (GDPs) as populations in these 
countries age and become more affluent. However, the 
trajectory of healthcare expenditure growth in middle-
income countries may be different compared to high-income 
countries.18 The coexistence of lifestyle related diseases 
together with an epidemiological profile comparable to that of 
low-income countries dictates the needs that health systems 
have to address. Middle-income economies are currently 
experiencing a rapid growth of non-communicable diseases 
such as type 2 diabetes and heart disease, while they still have 
to address communicable diseases such as malaria, cholera 
or tuberculosis. It is important to understand the trajectory 
of healthcare spending compared to GDP growth in order 
to understand the preparedness of health systems in middle-
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income countries and their resource allocation patterns to 
different types of health services.7 
This study aims to implement a comparison between middle- 
and high-income economies. This comparison takes into 
account the methodological recommendations from the 
previous literature. We collect a sample of 27 middle-income 
countries from Eastern Europe, Africa, Asia, the Middle 
East and Latin America that fulfills a set of economic and 
political criteria to construct a relatively homogenous sample 
of middle-income countries. Likewise, we select the group 
of 24 high-income economies from the OECD group of 
countries to estimate the updated per-capita health spending 
elasticity and compare it with the estimated elasticity in the 
sampled middle-income countries. This comparison serves 
two purposes. First, as high-income countries are extensively 
studied we aim to show that our methodology can produce 
results consistent with the existing literature for those 
countries.11,18,19 Second, we compare the elasticities in these 
two groups to explore whether increases in per capita wealth 
in middle-income countries produce expenditure responses 
comparable to those of high-income countries. 
We hypothesize that the aggregated income elasticity of health 
expenditures in middle-income countries would be less than 
one (meaning healthcare is a normal good), supporting 
findings from the previous literature, but would still be larger 
than that of high-income countries.6,7 Our reasoning is that 
with rapid economic modernization, such as accelerated 
income growth and urbanization, middle-income countries 
face quick changes in their epidemiological profile and 
consumption patterns that accelerate the growth of healthcare 
spending. While most middle-income countries still have 
higher OOP costs and larger populations, their governments 
have also been increasingly investing in healthcare services 
and new medical technologies.20 In addition, larger segments 
of the population in emerging countries still lack adequate 
access to healthcare safety nets, which can translate into 
higher OOP payments to new healthcare providers.21
By contrast, universal healthcare and well-developed 
insurance markets make healthcare less substitutable in 
high-income countries, leading to lower elasticities. Thus, we 
explore whether financial protection could partially explain 
this difference. Financial protection is a metric that has been 
used to evaluate whether insured individuals are effectively 
covered from the financial consequences of an adverse health 
event. The most widely used measure of financial protection 
in the literature is OOP healthcare spending.17,22 Annual 
OOP health expenditures have been used to evaluate whether 
new public health insurance programs have been effective at 
reducing the uncertainty of future health spending.22 Cross-
country comparative research on financial protection has 
estimated the incidence of catastrophic health spending at 
the country level.21,23 Also, economies of scale associated to 
universal health insurance coverage in high-income countries 
could translate into higher savings compared to healthcare 
financing in middle-income countries. 
Methods
Sample Selection 
To select a relatively homogeneous sample of middle-income 
countries for the analyses, three mutually exclusive political 
and economic criteria are used: (i) Global influence: middle-
income countries with G-20 membership, (ii) Rapid economic 
transformation: be part of the Dow-Jones and N-11 lists of 
emerging markets,24,25 (iii) Large internal markets: be classified 
as an “Emerging and Developing Country” by the IMF, have 
a population of at least 5 million people and a national GDP 
of at least $130 000 million in 2014.26 The 27 middle-income 
countries from Africa, the Middle East, South and East Asia, 
Eastern Europe and Latin America that fulfill at least two of 
the three criteria are listed in Table 1. 
Middle-income countries face different trajectories of health 
spending growth and development of healthcare markets 
compared to those of high-income countries. Hence, we 
compare the patterns of growth of healthcare spending with 
GDP in these emerging countries to those of 24 high-income 
countries of the OECD in order to discern potentially different 
patterns of growth in healthcare spending. 
Data Sources
The analyses utilize data from 27 emerging countries and 
24 high-income countries to compare their aggregate 
elasticity over a period of 20 years from 1995-2014. The data 
sources include the World Health Organization (WHO), 
the International Monetary Fund (IMF) and the US Census 
Bureau’s International data.27,28 Data on country health 
expenditure, public health expenditure and OOP spending 
are from WHO sources. Data on per-capita GDP is from the 
IMF. These measures are merged with international data from 
the US Census to estimate the share of the older adult (65 and 
above) population in each country, and their life expectancy.29
Health Spending
This study uses the econometric framework from the 
previous literature on the cross-country relationship between 
health expenditure and income.6,7 Consequently, the natural 
log of per-capita healthcare expenditures (health expenditure, 
subsequently) is the dependent variable in this study. It is 
estimated in terms of purchasing-power-parity (PPP) and 
expressed in current international dollars.28
Independent Variables
The main explanatory variable corresponds to the natural 
log of GDP per-capita (income, hereafter) estimated in PPP 
and expressed in international dollars.27 Additional variables 
(identified by previous literature as important determinants 
of cross-country differences in health expenditures) included 
in the analyses are the following: (i) the share of government 
health expenditure as a percentage of total health expenditure 
(government expenditures, subsequently) to capture any shifts 
in government financing of the health sector, (ii) the share 
of OOP health spending to investigate the role of financial 
protection, (iii) the percentage of the older adult population 
who are 65 years of age or older, and the percentage of 
children under 5 years of age, to control for heterogeneous 
demographic characteristics across countries, and to account 
for variation in demand for healthcare due to population 
patterns, and (iv) average life expectancy and infant mortality 
to account for supply-side factors. All continuous variables 
in the empirical analyses are included in natural logarithm 
form in the regression model. We conduct several sensitivity 
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analyses, which are included in the statistical appendix. 
Statistical Analyses 
All statistical analyses are conducted using Stata 14. The data 
are stratified by their status as middle- and high-income 
countries for a side-by-side comparison. All variables are 
included in their natural logarithm forms. All tests and 
regressions are repeated for middle- and high-income 
countries separately. The possibility of non-stationarity and 
cointegration of income, health expenditures and related 
explanatory variables in high-income countries has been 
stressed in the literature.12 Based on the results of unit root 
tests and test for serial correlation (described in more detail 
below), we implement the first-difference of study variables to 
de-trend the panel data,30 following prior literature.6,7 Further 
tests for unit roots and serial correlation confirm that using 
first differenced variables would address issues of unit roots 
within the model. We utilize Hausman and Breusch-Pagan 
Lagrange multiplier tests to determine that a fixed effects 
model with time fixed-effects is the best model compared to a 
random effects model (statistical appendix). 
Our regression approach can be summarized by the following 
regression equation: 
where yit represents health expenditures across countries (i = 
1,2,3…27 for middle-income countries and i=1,2..24 for high-
income countries) and across time (t = 1,2,3…20), the term 
Xit includes income and all additional explanatory variables 
described above. The term αi is the intercept for each country 
and δt is the intercept for time fixed-effects. The term uit 
represents the error term. 
Results 
Descriptive Statistics
Tables 1 and 2 show the mean values for each middle- and 
high-income country respectively. Over the study period 
(1997-2014), the UAE and Saudi Arabia reported the highest 
GDP growth rates whereas Russia and Romania had the lowest 
Table 1. Economic Indicators Across Sampled Middle-Income Economies (1995-2014)a
Country GDP Per Capita PPP
Per Capita 
HE
HE as % 
of GDP
Government HE 
as % of Total HE
OOP Expenditure 
as % of Total HE
Percent 65 
and Over
Life 
Expectancy
Infant Mortality Rate 
(deaths/1000 Live 
Births)
Algeria  10 435  475 4.34 72.56 26.47 4.59 73.42 51.00
Argentina  15 078  1049 7.31 56.83 27.74 10.45 75.34 51.20
Brazil  11 521  893 7.60 43.50 33.69 5.98 70.75 96.90
Chile  15 204  1032 6.64 46.31 41.70 7.98 76.56 51.20
China  5899  288 4.65 45.72 47.02 7.66 72.67 84.50
Colombia  8832  599 6.81 73.16 18.81 5.36 72.66 28.00
Czech Republic  21 926  1534 6.90 87.43 11.80 14.63 75.89 1.20
Egypt  8367  429 5.07 40.13 57.15 3.93 70.62 142.90
Hungary  18 267  1386 7.53 70.42 24.64 15.69 72.79 1.90
India  3138  136 4.29 26.23 66.40 4.85 64.08 36.10
Indonesia  6574  171 2.50 36.83 47.29 5.29 69.25 30.50
Iran  12 934  775 5.68 41.44 52.53 4.72 67.97 73.25
Malaysia  16 478  595 3.51 56.07 33.66 4.38 72.03 95.20
Mexico  13 252  767 5.69 46.08 50.78 5.41 74.67 106.85
Nigeria  3617  131 3.53 28.53 67.78 2.89 48.21 133.30
Pakistan  3477  99 2.83 26.91 63.59 4.06 63.55 87.90
Peru  7383  361 4.82 55.55 36.49 5.48 70.34 160.90
Philippines  4437  173 3.76 38.23 50.59 3.77 68.96 151.20
Poland  15 830  1001 6.19 70.59 25.96 13.00 74.72 66.50
Romania  12 660  644 4.86 79.53 20.10 14.03 72.06 97.35
Russia  16 976  1060 6.12 60.44 32.67 13.09 67.27 50.80
Saudi Arabia  40 359  1504 3.71 67.98 20.46 2.71 72.73 97.00
South Africa  9769  809 8.27 44.00 10.85 4.67 55.33 129.45
Thailand  10 328  392 3.75 65.57 24.56 7.35 71.89 55.85
Turkey  13 262  683 4.97 72.02 21.70 5.82 70.84 82.55
UAE  74 483  2113 2.91 69.88 21.37 0.85 75.07 1.50
Venezuela  14 101  694 4.91 39.15 54.68 5.04 72.95 86.90
Total (N = 27)  14 614  733 5.15 54.11 36.68 6.81 70.09 76.00
SD  14 456  551 1.73 17.54 17.41 3.99 6.47 56.97
Min  1522  52 1.93 19.59 6.49 0.76 44.00 1.00
Max  92 863  2454 9.38 90.89 75.23 17.83 78.40 172.00
No. of observations 540 540 540 540 540 539b 539b 540
Abbreviations: GDP, gross domestic product; HE, health expenditure; PPP, purchasing-power-parity; OOP, out-of-pocket.
a Mean values between 1995-2014. Data on country HE, public HE and OOP spending are from WHO sources. Data on GDP growth is from the IMF. Share of 
elderly population is from the US Census international data.
b Data missing for Egypt for 1995.
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growth. Average per capita GDP was the highest in UAE and 
Saudi Arabia, while Nigeria, India and Pakistan reported the 
lowest values. In the case of high-income countries, Israel 
and Ireland reported the highest average growth rates and 
Germany and Japan had the lowest growth rates during the 
study period. Portugal, South Korea and Israel had the lowest 
GDP per capita and Luxembourg, Norway and Switzerland 
had the highest GDP per capita. 
The sampled middle-income countries that allocated a 
higher share of GDP to healthcare were South Africa, Brazil 
and Hungary, while Indonesia, UAE and Pakistan allocated 
the lowest. In the case of per-capita health spending, the 
Czech Republic, UAE and Saudi Arabia reported the highest 
expenditures, compared to Pakistan, Nigeria and India that 
reported the lowest. In the case of high-income countries, 
South Korea, Luxembourg and Ireland reported the lowest 
share of health spending as a share of GDP whereas the 
United States, Switzerland and France reported the highest. 
In the case of per capita health spending, the United States, 
Luxembourg and Norway had the highest values and South 
Korea, Israel and Portugal reported the lowest.
From the financial protection perspective, among middle-
income countries, Nigeria, Pakistan and Egypt reported the 
highest OOP share of health spending, while Romania, Saudi 
Arabia and South Africa reported the lowest. In the case of 
high-income countries, South Korea, Greece and Switzerland 
reported the highest share of OOP spending from total health 
expenditures while Luxemburg, the Netherlands and France 
reported the lowest. 
Eastern European countries in the sample (Hungary, Czech 
Republic, Romania, Poland and Russia) had the highest shares 
of the elderly population (65 and over), while Nigeria, Saudi 
Arabia and the UAE had the lowest share. These data trends 
suggest a more advanced demographic transition in Eastern 
Europe. In the case of high-income countries, Italy, Japan and 
Germany had the highest shares of the older adult population 
and South Korea, Israel and Ireland had the lowest share of 
older adults.
Model Selection
Detailed results of the model fit and other tests described in 
this section are provided in the statistical appendix. First, we 
conducted a series of unit root tests to check for stationarity in 
variables with logarithmic raw form or by de-trending them. 
Non-significant results from these tests indicated that the 
presence of unit root could not be rejected. Then, we tested 
Table 2. Economic Indicators across Large High-Income Economies (1995-2014)
Country GDP Per Capita PPP
Per 
Capita HE
HE as % 
of GDP
Government HE 
as % of Total HE
OOP Expenditure 
as % of Total HE
Percent 65 
and Over
Life 
Expectancy
Infant Mortality Rate 
(deaths/1000 Live Births)
Australia 34 807 2986 8.44 67.03 18.33 13.01 80.55 4.25
Austria 36 203 3823 10.46 74.92 16.15 16.59 79.03 1.10
Belgium 34 091 3177 9.14 76.23 19.21 17.08 78.62 1.45
Canada 34 504 3401 9.71 70.42 15.00 14.28 80.50 47.00
Finland 32 587 2749 8.31 73.50 20.34 16.18 78.44 1.00
France 32 521 3465 10.56 78.36 7.10 16.29 80.01 72.35
Germany 34 672 3663 10.48 77.88 12.62 18.41 78.81 67.25
Greece 24 238 2152 8.77 60.20 35.21 18.31 78.99 1.60
Iceland 33 199 2976 8.95 81.68 17.16 11.96 80.47 1.00
Ireland 37 934 2846 7.30 72.93 15.85 11.30 78.45 1.00
Israel 24 149 1805 7.45 63.04 26.52 9.87 79.88 2.00
Italy 31 477 2683 8.43 74.21 22.84 19.22 80.52 50.00
Japan 29 640 2519 8.32 81.57 15.09 19.74 82.07 77.40
Luxembourg 74 026 5327 7.08 86.84 9.96 14.56 78.94 1.00
The Netherlands 38 143 3527 9.01 74.91 7.12 14.60 79.26 2.00
New Zealand 26 486 2441 8.89 79.92 13.77 12.37 79.28 1.00
Norway 53 855 4827 8.91 83.82 15.39 15.26 79.48 1.00
Portugal 22 703 2119 9.20 67.26 23.62 16.79 77.22 1.40
South Korea 22 655 1316 5.41 51.48 39.09 9.04 77.77 56.70
Spain 27 761 2315 8.21 72.51 22.16 16.73 79.99 45.80
Sweden 35 083 3385 9.41 83.35 14.90 17.87 80.42 1.00
Switzerland 45 145 4816 10.56 59.65 29.87 15.90 80.86 1.00
UK 31 053 2567 8.06 81.56 10.26 16.07 78.70 93.80
USA 42 062 6444 15.04 45.39 13.20 12.83 77.57 63.65
Total (N = 24) 34 958 3222 9.00 72.44 18.36 15.19 79.41 24.87
SD 13 085 1492 1.98 10.71 8.19 3.08 1.76 32.91
Min 12 079 444 3.67 37.53 5.22 5.82 73.60 1.00
Max 96 035 9318 17.14 92.81 53.13 25.77 84.50 120.00
Observations 480 480 480 480 480 479a 479a 479a
Abbreviations: GDP, gross domestic product; HE, health expenditure; PPP, purchasing-power-parity; OOP, out-of-pocket.
a Data missing for Ireland for 1995.
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the first differenced data for the same specifications. The 
significant results with the first differenced variables indicated 
absence of unit roots and hence, we used first differenced 
variables for the rest of the analyses. 
Although our preferred regression model based on earlier 
literature is the fixed effects model, we conducted Hausman 
tests to confirm this choice by comparing fixed and random 
effects models, with a single covariate (first differenced 
logarithm of per capita GDP) and then again with all 
covariates. Results from these tests indicate that a fixed 
effects model was a better fit for the data. We confirmed these 
results with Breusch-Pagan Lagrange multiplier tests, where 
non-significant P values indicate that ordinary least squares 
(OLS) with year fixed effects is a better fit compared to the 
corresponding random effects models. 
We concluded this section of the analyses conducting 
the Pesaran test for cross-sectional dependence (CSD) 
and contemporaneous correlation and Woolridge test for 
autocorrelation. The non-significant F-values from these 
tests indicate that our preferred models do not have CSD or 
autocorrelation issues (details are provided in the statistical 
appendix). 
Elasticities
Table 3 summarizes the main panel regression analyses with 
robust standard errors. The reduced models estimate the basic 
relationship between health expenditures and GDP growth, 
without year fixed-effects or additional covariates. The results 
confirm a positive relationship between income and health 
spending with an aggregated income elasticity of health 
spending less than one. When time fixed-effects and all the 
explanatory variables are fitted into the full model, effect sizes 
change from 0.49 to 0.51 for the middle-income countries 
and from 0.55 to 0.50 for high-income economies. All these 
coefficients are statistically significant. Comparisons of the 
coefficients across the models indicate that the coefficients 
are statistically different. In addition, the aggregate elasticity 
is less than one. The magnitude of the estimated aggregate 
income elasticity of health spending for emerging countries 
is essentially identical to the one in high-income economies. 
Most explanatory variables are not statistically significant in 
the full models, including OOP spending. The only exceptions 
were growth in government spending and in the share of the 
older adult population that were statistically significant in the 
case of high-income countries.
Following the previous literature, we considered including 
variables that represent governance factors, voice and 
accountability and regulatory control over the same period.6 
However, many emerging countries included in our study 
do not have these measures reported consistently leading 
to a very small sample size. Hence, we do not include those 
variables in our analyses although they influence the cost, 
quality, outcomes and effectiveness of healthcare.
Discussion
As countries develop and become more affluent, spending 
priorities of households and governments change. The 
literature on the cross-country relationship between health 
expenditure and income in high-income countries has 
investigated whether healthcare can be considered a superior 
good (elasticity >1) or a normal good (elasticity <1). In other 
words, the question is whether countries spend more, the 
same or less on healthcare as they become richer. This is an 
important issue for middle-income economies as their health 
Table 3. Panel Analysis: Determinants of Per Capita Healthcare Expenditure
∆Log HE as % of GDP
Middle-Income Countries High-Income Countries
Reduced Model Full Model Reduced Model Full Model
∆Log GDP per capita
0.49*** 0.51*** 0.55*** 0.50***
(0.10) (0.10) (0.09) (0.11)
∆Log government HE as % of total HE
 0.05  0.30*
 (0.14)  (0.22)
∆Log OOP. HE as % of total HE
-0.06 0.07
(0.08) (0.15)
∆Log life expectancy
 0.32  0.30
 (0.27)  (0.65)
∆Log infant mortality
 -0.01  0.00
 (0.01)  (0.00)
∆Log Pop. >65
 0.03  -0.55*
 (0.36)  (0.24)
∆Log Pop. <5
 0.14  -0.11
 (0.18)  (0.15)
Constant
0.04*** 0.03*** 0.03*** 0.04***
(0.00) (0.01) (0.00) (0.01)
N 513 512 456 455
No. of countries 27 27 24 24
t (years) 20 20 20 20
R-squared 0.06 0.07 0.14 0.16
AIC -1177.70 -1171.50 -1695.79 -1693.26
BIC -1173.46 -1146.07 -1691.67 -1668.53
Abbreviations: GDP, gross domestic product; HE, health expenditure; OOP, out-of-pocket; AIC, Akaike Information Criterion; BIC, Bayesian Information Criterion.
* P < .05; ** P < .01; *** P < .001.
Robust standard errors are in parentheses.
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systems are trying to keep pace with their rapid economic 
development. Knowing how economic growth affects health 
spending can provide useful information to government 
planners and international organizations. In addition, 
comparing the respective elasticities of middle-income 
countries with those of currently high-income countries 
can provide new insights about possible consequences of 
government expenditures, financial protection, and growing 
shares of older populations across different stages of economic 
development. 
This study is among the first studies that extend the analysis 
of income elasticity of health spending to middle-income 
countries.6,7 One of the differences between previous studies 
and our study is the selection of countries included in the 
analysis. While previous studies include more heterogeneous 
set of countries in broad income categories such as middle- or 
low-income countries as defined by World Bank, our data is 
more homogenous and representative of a subset of middle-
income countries, which were chosen based on economic, 
political and demographic criteria described earlier. Our 
estimates use the latest econometric techniques that have been 
implemented in recent studies to address methodological 
issues such as serial-correlation and co-integration that are 
inherently present in time-series data.6,7
While previous research has used a comprehensive sample 
of middle-income countries, we have followed the advice 
from the recent literature that recommends conducting 
cross-country comparison in more homogenous subsets of 
countries.3,4 In this study we focus on emerging countries with 
large populations, economies and global influence. In contrast 
to the previous findings, our estimates of income elasticity of 
health spending are nearly identical to those of high-income 
countries. This finding could possibly suggest the convergence 
of health spending and income growth dynamics between 
sampled middle- and high-income countries. 
In addition, our comparison looks at the share of OOP 
spending as a percentage of health spending to examine the 
potential role of financial protection in explaining differences 
in the income elasticity of health spending between middle- 
and high-income countries. More fragmented coverage and 
less regulated healthcare markets in middle-income countries 
could suggest less financial protection and a higher share of 
income growth allocated to health spending. In high-income 
countries, governments are the main financers and sometimes 
even the main providers of healthcare. By contrast, the size 
of the private delivery system that is financed through OOP 
spending is larger in middle-income countries.2 In contrast 
with high-income economies where private insurers negotiate 
payments with private providers, private health insurance 
markets in middle-income countries are still in their initial 
formative stages.
With a few exceptions, most countries in our sample of 
middle-income countries have fragmented health systems 
that offer different types of coverage to different populations. 
In contrast with most high-income countries where universal 
healthcare or near universal healthcare coverage takes full 
advantage of economies of scale, the fragmentation of health 
systems in many middle-income countries may increase 
administration costs that ultimately are reflected in higher 
overall health expenditures as incomes rise. According to 
our findings, however, the OOP share of health spending is 
non-statistically significant in both middle- and high-income 
countries. Future research should investigate whether this 
relationship holds over time as healthcare funders in both sets 
of countries reduce costs partly by increasing the cost sharing 
among healthcare users. 
Our study identified a positive and small but statistically 
significant relationship between growth in government 
expenditures and the aggregate income elasticity of health 
expenditure in high-income countries. This association may 
be suggestive of the increasing role of government financing 
in the health sector of this group of countries. In 2014, the 
governments of high-income countries were responsible 
for approximately 65% of national health expenditures.31 By 
contrast, the 27 governments of emerging countries analyzed 
in this study were responsible for approximately 35% of 
national health expenditures.28 If governments in middle-
income countries continue to increase their financing of 
the health sector and eventually reach the share observed in 
high-income countries, it is uncertain whether the income 
elasticity of health spending would go any lower. 
As populations grow older, they are expected to spend more 
on healthcare as a consequence of increased utilization by the 
older adult population. However, this study did not find any 
evidence that growth in the share of the elderly population 
is related to health expenditure growth among the sampled 
group of middle-income countries. Growth in population 
ageing was negative and statistically significant in high-income 
countries only. These results may suggest a weak influence of 
these factors in driving overall health expenditure growth. 
Future research could explore whether related independent 
variables that could impact health spending, such as the 
availability of new medical technologies, are significantly 
associated with the income elasticity of health spending once 
population ageing accelerates in middle- and high-income 
countries.20 
Middle-income countries can benefit from shared knowledge 
on how to pair accelerated economic development with more 
effective, efficient and fair healthcare systems. The results 
of this study also suggest that government planners in the 
sampled middle-income countries should still find ways to 
pair income growth with rapidly changing health systems 
where health-spending evolution may differ from that of 
current patterns among high-income countries. 
Study Limitations
While this analysis is informative on the aggregate level 
of health spending growth and income, some limitations 
should be acknowledged. Country-level results are difficult 
to examine in regards to the interaction of income and 
health expenditure growth without accounting for other 
less aggregate measures such as income inequality, quality 
of care, changing health status and increasing education and 
living standards.11,32 Non-linear and changing relationships 
across countries should be further investigated.18,19 While 
data sources for most countries in this study are reliable 
and results remain robust to different specifications, cross-
country differences do exist in data recording standards and 
methodologies and hence, the results should be interpreted 
with caution. 
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Conclusion
This study shows that health expenditures in emerging 
countries can still be considered a normal good rather than 
a superior good. Our point estimates suggest that the income 
elasticity of health spending is similar in middle- and high-
income countries. Our findings contrast with previous 
research that used a broader sample of middle-income 
countries. It is currently uncertain whether health expenditure 
dynamics will change as middle-income countries transition 
towards universal health coverage and their healthcare 
markets become more sophisticated. We find no evidence 
that differences in financial protection and population ageing 
growth rates may take them in a different trajectory as the one 
experienced by current high-income countries.
Ethical issues 
Secondary data analyses from publicly available sources are not subject to IRB 
review at UCLA or CSULB.
Competing interests 
Authors declare that they have no competing interests. 
Authors’ contributions 
AVB: study conception, research design, data analysis and interpretation, and 
manuscript editing. SVS: data analysis and manuscript editing.
Authors’ affiliations
1Department of Health Policy and Management, Fielding School of Public 
Health, University of California, Los Angeles, CA, USA. 2Department of Health 
Care Administration, California State University, Long Beach, CA, USA.
Endnotes
[1] Income elasticity is defined as the percentage change in healthcare 
expenditure associated with 1% change in income.
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Statistical Appendix 
1. Lagged Unit Root Tests
Lagged  Variables
Without Trend With Trend
3ADF 2ADF 1ADF 0ADF 3ADF 2ADF 1ADF 0ADF
Log GDP per capita 0.95 1.94 0.92 -0.60 -0.19 0.38 -2.64** 7.72
Log HE as % of GDP -0.14 1.22 2.75 4.00 5.20 2.87 1.58 3.31
Log Pop. >65 5.04 4.86 5.30 4.78 5.64 5.94 7.16 9.14
Log % of Govt. HE 0.65 0.11 -1.49 0.01 3.22 2.90 1.97 2.47
Log OOP as % of private HE -1.06 -1.88* -1.70* -1.00 1.82 0.64 0.92 2.39
Log Life Exp. - - - - - - - -
Log infant mortality - - - - - - - -
Log Gini coefficient - - - - - - - -
First Differenced Lagged Variables
Without Trend With Trend
3ADF 2ADF 1ADF 0ADF 3ADF 2ADF 1ADF 0ADF
∆Log GDP per capita -3.15** -3.72** -6.53** -4.52** -1.90* -1.77* -4.62** -3.00**
∆Log HE as % of GDP 0.88 -3.05** -4.14** -8.21** -0.81 -3.07** -2.28* -6.8**
∆Log Pop. >65 2.57 2.25 2.32 -1.88* 2.78 2.11 2.23 -3.44**
∆Log % of Govt. HE -0.84 -1.64* -4.74** -10.74** -2.67* -0.81 -3.60** -9.64**
∆Log OOP as % of private HE -1.58* -3.97** -4.89** -10.53** -0.73 -3.35** -3.48** -9.25**
∆Log Life Exp. -4.34** -3.26** -6.24** -16.47** 0.00** -2.02* -5.12** -15.55**
∆Log infant mortality -8.87** -4.86** -10.74** -19.96** -7.54** -3.13** -10.24** -17.62**
∆Log Gini coefficient - - - - - - - -
Abbreviations: GDP, gross domestic product; HE, health expenditure; OOP, out-of-pocket; ADF, augmented Dickey-Fuller Regressions.
Hausman test to test between fixed and random effects models – significant P value indicates FE model is preferred 
FE RE Chi2 P value Preferred Model
Middle-income countries Simple model - One covariate fd_ln_gdp_pc 0.4881235 0.5892946 7.58 0.0059 FE
High-income countries Simple model - One covariate fd_ln_gdp_pc 0.5467499 0.6034603 10.66 0.0011 FE
Middle-income countries Multiple covariates fd_ln_gdp_pc 0.5027975 0.5949999 8.69 0.1918 -
High-income countries Multiple covariates fd_ln_gdp_pc 0.5006531 0.5594028 16.16 0.0129 FE
Breusch-Pagan Lagrange multiplier tests for random effects – a non-significant P value indicates that OLS is preferred to RE. 
As OLS with dummy years is similar to FE, we take it to indicate that FE is preferred to RE from this test.  
Middle-income countries Chi2 P Value Preferred Model
High-income countries Multiple covariates fd_ln_gdp_pc 0.5949999 0 1 OLS
Multiple covariates fd_ln_gdp_pc 0.5594028 0 1 OLS
Pesaran test for CSD and contemporaneous correlation – non-significant results indicate no CSD
Middle-income countries Chi2 P Value Preferred Model
High-income countries Multiple covariates fd_ln_gdp_pc 0.5949999 0 1 No CSD
Multiple covariates fd_ln_gdp_pc 0.5594028 0 1 No CSD
Woolridge test for autocorrelation in panel data – non-significant results indicate no CSD 
Middle-income countries F Value P Value Preferred Model
High-income countries Multiple covariates fd_ln_gdp_pc 0.7351903 1.129 0.2977 no autocorrelation
Multiple covariates fd_ln_gdp_pc 0.4800522 0.036 0.8518 no autocorrelation
Abbreviations: CSD, cross sectional dependence; FE, fixed effects; OLS, ordinary least squares.
2. Model Fit Tests
